Mark Namchuk

(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18

Woods Wannamaker, Robert M. D. Davies, Mark Namchuk et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 309 citations

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland et al. · Molecular Cancer Therapeutics · 2017 · 225 citations

Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.

John Kim, Mark Namchuk, Teodorica L. Bugawan et al. · The Journal of Experimental Medicine · 1994 · 191 citations · Full text

Immunology, Pathology, Insulin Signaling +20

The Role of Sugar Substituents in Glycoside Hydrolysis

Mark Namchuk, John D. McCarter, Adam Becalski et al. · Journal of the American Chemical Society · 2000 · 191 citations

Bioorganic Chemistry, Engineering, Biochemistry +13

Mechanism of Agrobacterium .beta.-glucosidase: kinetic analysis of the role of noncovalent enzyme/substrate interactions

Mark Namchuk, Stephen G. Withers · Biochemistry · 1995 · 168 citations

Bioorganic Chemistry, Glycobiology, Polysaccharide +16